LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention

Recruiting now · Phase 4

Conditions studied: Preeclampsia Severe, Toxemia Of Pregnancy, Preeclampsia, Pregnancy Complications, Hypertension, Pregnancy-Induced, Gestational Hypertension

In brief

Preeclampsia is a major cause of maternal and perinatal morbidity and mortality worldwide. Low-dose aspirin started in the first trimester reduces the risk of preeclampsia in high-risk women. Low molecular weight heparin (LMWH) has shown potential benefits in addition to aspirin for preventing preeclampsia through its anticoagulant, anti-inflammatory, and endothelial protective effects. However, current evidence is limited and conflicting regarding the added value of LMWH to aspirin. This randomized controlled trial aims to evaluate the efficacy of combined aspirin and LMWH, compared to aspirin alone, for reducing the incidence of preeclampsia in high-risk gravidas.

Key facts

Study ID
NCT07361679
Run by
Alexandra Hospital, Athens, Greece
People needed
100
Starts
2023-01-18
Expected to finish
2027-07-01
Last updated by the study team
2026-01-23

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.